Tanvex BioPharma (TPE:6541) ROC (Joel Greenblatt) %: -62.93% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6541 Tanvex BioPharma Inc TPE:6541
57 GF Score
Price NT$39.10
GF Value NT$256.28
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Tanvex BioPharma ROC (Joel Greenblatt) %?

Tanvex BioPharma TPE:6541 +1.82% 57 ROC (Joel Greenblatt) % is -62.93% as of Dec. 2025. GuruFocus rates TPE:6541 with a GF Score™ of 57/100 and a GF Value™ of NT$256.28 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,323 Biotechnology companies, Tanvex BioPharma ranks better than 65.61% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Tanvex BioPharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -62.93%.

The historical rank and industry rank for Tanvex BioPharma's ROC (Joel Greenblatt) % or its related term are showing as below:

TPE:6541' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -272.37   Med: -104.14   Max: -61
Current: -61

During the past 13 years, Tanvex BioPharma's highest ROC (Joel Greenblatt) % was -61.00%. The lowest was -272.37%. And the median was -104.14%.

TPE:6541's ROC (Joel Greenblatt) % is ranked better than
65.61% of 1323 companies
in the Biotechnology industry
Industry Median: -297.52 vs TPE:6541: -61.00

Tanvex BioPharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 11.50% per year.


Tanvex BioPharma  (TPE:6541) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Tanvex BioPharma ROC (Joel Greenblatt) % Related Terms


Tanvex BioPharma ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Tanvex BioPharma's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tanvex BioPharma ROC (Joel Greenblatt) % Chart

Tanvex BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -74.17 -72.82 -99.55 -68.32 -61.99

Tanvex BioPharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -56.36 -83.92 -54.82 -43.46 -62.93

TPE:6541 vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Tanvex BioPharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tanvex BioPharma ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Tanvex BioPharma's ROC (Joel Greenblatt) % falls into.


TPE:6541
57GF Score
Tanvex BioPharma Inc TPE:6541
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tanvex BioPharma ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(100.303 + 399.615 + 104.373) - (421.737 + 0 + 99.551)
=83.003

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(30.2 + 416.478 + 78.761) - (507.911 + 0 + 80.117)
=-62.589

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Tanvex BioPharma for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1636.912/( ( (2358.676 + max(83.003, 0)) + (2760.887 + max(-62.589, 0)) )/ 2 )
=-1636.912/( ( 2441.679 + 2760.887 )/ 2 )
=-1636.912/2601.283
=-62.93 %

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -62.93% mean?
Tanvex BioPharma (TPE:6541) has a ROC (Joel Greenblatt) % of -62.93% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Tanvex BioPharma and its competitors. According to the industry distribution chart, Tanvex BioPharma ranks #455 out of 1323 companies in the Biotechnology industry, placing it in the top 34.4%.
Is Tanvex BioPharma's ROC (Joel Greenblatt) % too high?
Tanvex BioPharma's current ROC (Joel Greenblatt) % is -62.93%. Based on the distribution chart, Tanvex BioPharma ranks #455 out of 1323 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tanvex BioPharma ranks #455 out of 1323 companies for ROC (Joel Greenblatt) %. This puts Tanvex BioPharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Tanvex BioPharma and its competitors. Tanvex BioPharma's current ROC (Joel Greenblatt) % is -62.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$256.28, compared to a current price of NT$39.10 — trading 84.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is -62.93%. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current ROC (Joel Greenblatt) % is -62.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?

Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued. The current stock price of NT$39.10 is trading 84.7% below its estimated GF Value™ of NT$256.28. GuruFocus considers Tanvex BioPharma to be Possible Value Trap.

Key valuation signals for TPE:6541:

  • ROC (Joel Greenblatt) %: -62.93%
  • GF Value™: NT$256.28 vs. price of NT$39.10 (84.7% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tanvex BioPharma Business Description

Address No. 12-2, Shengyi Road, Section 2, 6th Floor, Hsinchu County, Zhubei, TWN, 106
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score

Get the complete analysis for TPE:6541

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$39.10
Price
NT$256.28
GF Value